184 related articles for article (PubMed ID: 28654954)
1. Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial.
Berg M; Welty TE; Gidal BE; Diaz FJ; Krebill R; Szaflarski JP; Dworetzky BA; Pollard JR; Elder EJ; Jiang W; Jiang X; Switzer RD; Privitera MD
JAMA Neurol; 2017 Aug; 74(8):919-926. PubMed ID: 28654954
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and safety of a new generic lurasidone: a phase I bioequivalence study in healthy Chinese subjects.
Liu Z; Xue J; Deng Q; Wang Y; Zhang L; Liu L; Xiao N; Chang T; Cui Y; Cheng Y; Liu G; Wang W; Zhou Y; Yang W; Qu X; Chen J; Zhao Y; Wang Z; Yang H
Naunyn Schmiedebergs Arch Pharmacol; 2024 Apr; ():. PubMed ID: 38643450
[TBL] [Abstract][Full Text] [Related]
3. Use of Therapeutic Drug Monitoring, Electronic Health Record Data, and Pharmacokinetic Modeling to Determine the Therapeutic Index of Phenytoin and Lamotrigine.
Ku LC; Wu H; Greenberg RG; Hill KD; Gonzalez D; Hornik CP; Berezny A; Guptill JT; Jiang W; Zheng N; Cohen-Wolkowiez M; Melloni C
Ther Drug Monit; 2016 Dec; 38(6):728-737. PubMed ID: 27764025
[TBL] [Abstract][Full Text] [Related]
4. Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products by the US Food and Drug Administration.
Davit BM; Chen ML; Conner DP; Haidar SH; Kim S; Lee CH; Lionberger RA; Makhlouf FT; Nwakama PE; Patel DT; Schuirmann DJ; Yu LX
AAPS J; 2012 Dec; 14(4):915-24. PubMed ID: 22972221
[TBL] [Abstract][Full Text] [Related]
5. In Vitro In Vivo Extrapolation and Bioequivalence Prediction for Immediate-Release Capsules of Cefadroxil Based on a Physiologically-Based Pharmacokinetic ACAT Model.
Rahim N; Naqvi SBS
AAPS PharmSciTech; 2024 May; 25(5):100. PubMed ID: 38714602
[TBL] [Abstract][Full Text] [Related]
6. Examining therapeutic equivalence between branded and generic warfarin in Brazil: The WARFA crossover randomized controlled trial.
Gomes Freitas C; Walsh M; Coutinho EL; Vincenzo de Paola AA; Atallah ÁN
PLoS One; 2021; 16(4):e0248567. PubMed ID: 33793580
[TBL] [Abstract][Full Text] [Related]
7. Refilling and switching of antiepileptic drugs and seizure-related events.
Gagne JJ; Avorn J; Shrank WH; Schneeweiss S
Clin Pharmacol Ther; 2010 Sep; 88(3):347-53. PubMed ID: 20631693
[TBL] [Abstract][Full Text] [Related]
8. Current methodology to assess bioequivalence of levothyroxine sodium products is inadequate.
Blakesley VA
AAPS J; 2005 Mar; 7(1):E42-6. PubMed ID: 16146348
[TBL] [Abstract][Full Text] [Related]
9. Influence of cirrhosis on lamotrigine pharmacokinetics.
Marcellin P; de Bony F; Garret C; Altman C; Boige V; Castelnau C; Laurent-Puig P; Trinchet JC; Rolan P; Chen C; Mamet JP; Bidault R
Br J Clin Pharmacol; 2001 May; 51(5):410-4. PubMed ID: 11421997
[TBL] [Abstract][Full Text] [Related]
10. Development of a New Bioequivalent Omeprazole Product.
Kumisbek G; Vetchý D; Kadyrbay A
Medicina (Kaunas); 2024 Mar; 60(3):. PubMed ID: 38541153
[No Abstract] [Full Text] [Related]
11. Generic antiepileptic drugs: current controversies and future directions.
Privitera MD
Epilepsy Curr; 2008; 8(5):113-7. PubMed ID: 18852829
[TBL] [Abstract][Full Text] [Related]
12. The use of GA-RxODE (Genetics Algorithms and Running simulations from Ordinary Differential Equations-based model) method to optimize bioequivalence studies.
Nuske EO; Morozov M; Alejandro Serra H
Pharmacol Res Perspect; 2021 Oct; 9(5):e00824. PubMed ID: 34609078
[TBL] [Abstract][Full Text] [Related]
13. Bioequivalence trials for the approval of generic drugs in Saudi Arabia: a descriptive analysis of design aspects.
Althunian TA; Alzenaidy BR; Alroba RA; Almadani OA; Alqahtani FA; Binajlan AA; Almousa AI; Alamr DK; Al-Mofada MS; Alsaqer NY; Alarfaj HA; Bahlewa AA; Alharbi MA; Alhomaidan AM; Alsuwyeh AA; Alsaleh AA
BMC Med Res Methodol; 2024 Apr; 24(1):82. PubMed ID: 38580928
[TBL] [Abstract][Full Text] [Related]
14. Avoidance of generic competition by Abbott Laboratories' fenofibrate franchise.
Downing NS; Ross JS; Jackevicius CA; Krumholz HM
Arch Intern Med; 2012 May; 172(9):724-30. PubMed ID: 22493409
[TBL] [Abstract][Full Text] [Related]
15. A Bioequivalence Test by the Direct Comparison of Concentration-versus-Time Curves Using Local Polynomial Smoothers.
Tian S; Chang HH; Orange D; Gu J; Suárez-Fariñas M
Comput Math Methods Med; 2016; 2016():4680642. PubMed ID: 28050196
[TBL] [Abstract][Full Text] [Related]
16. Adaptive designs for IVPT data with mixed scaled average bioequivalence.
Lim D; Rantou E; Kim J; Choi S; Choi NH; Grosser S
Pharm Stat; 2023; 22(6):1116-1134. PubMed ID: 37555542
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous Pharmacokinetics-Based Bioequivalence: A Clinical Dermal Open Flow Microperfusion Verification Study Using Lidocaine and Prilocaine Combination Topical Products.
Tiffner KI; Ramezanli T; Boulgaropoulos B; Birngruber T; Bodenlenz M; Lackner BC; Raml R; Jiang Y; Raney SG; Sinner F
Eur J Pharm Sci; 2024 Jun; ():106827. PubMed ID: 38857708
[TBL] [Abstract][Full Text] [Related]
18. Evaluating gender effect in the generic bioequivalence studies by physiologically based pharmacokinetic modeling - A case study of dextromethorphan modified release tablets.
Gundeti M; Murthy A; Jamdade S; Ahmed T
Biopharm Drug Dispos; 2024 May; ():. PubMed ID: 38776407
[TBL] [Abstract][Full Text] [Related]
19. A Two-Way Proposal for the Determination of Bioequivalence for Narrow Therapeutic Index Drugs in the European Union.
Paixao P; Garcia Arieta A; Silva N; Petric Z; Bonelli M; Morais JAG; Blake K; Gouveia LF
Pharmaceutics; 2024 Apr; 16(5):. PubMed ID: 38794260
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of generic drugs with respect to brand formulation.
Gallelli L; Palleria C; De Vuono A; Mumoli L; Vasapollo P; Piro B; Russo E
J Pharmacol Pharmacother; 2013 Dec; 4(Suppl 1):S110-4. PubMed ID: 24347975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
